Skip to main content
Signal8
Launch Terminal

Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Jazz Pharmaceuticals plc logo

Jazz Pharmaceuticals plc

NASDAQ:JAZZHealthcare
+3.92%$215.98
AH$215.98+0.00%vs close
Mkt Cap$14.02B
Float62.17M
O/S64.91M
Vol
$ Vol
RVOL
Inst Own99.9%
SI9.4%
Earnings
Dilution
Jazz Pharmaceuticals plc logoNASDAQ:JAZZ$215.98+3.92%
Upcoming Catalysts
Phase Distribution
206 lead-sponsored trials·21 active·132 completed
Early Phase 11
Phase 129
Phase 1/28
Phase 259
Phase 2/34
Phase 370
Phase 410
Not applicable25
(90 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Completed

    Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients

    Xyrem (X), Zolpidem (Z)

    Obstructive Sleep Apnea Syndrome

    Enrollment
    60
    Start
    Nov 2003
    Primary Completion
    Jun 2005
    Completion
    Nov 2005
    NCT00086281
  • Phase 4
    Withdrawn

    A Study to Compare the Efficacy of Rapydan Versus Tetracaine Gel

    Rapydan, tetracaine gel

    Healthy, Anesthesia

    Enrollment
    0
    Start
    Apr 2008
    Primary Completion
    Dec 2008est.
    Completion
    -
    NCT00670696
  • Phase 4
    Completed

    A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients

    Sativex, Placebo

    Multiple Sclerosis, Spasticity

    Enrollment
    121
    Start
    Jan 2012
    Primary Completion
    May 2013
    Completion
    May 2013
    NCT01964547
  • Phase 4
    Withdrawn

    Investigation of Cognitive Outcomes With Cannabidiol Oral Solution

    GWP42003-P

    Lennox-Gastaut Syndrome

    Enrollment
    0
    Start
    Oct 2020est.
    Primary Completion
    Dec 2021est.
    Completion
    Dec 2021est.
    NCT04133480
  • Phase 4
    Completed

    An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy

    JZP-258

    Narcolepsy

    Enrollment
    62
    Start
    Mar 2021
    Primary Completion
    Nov 2022
    Completion
    Nov 2022
    NCT04794491
  • Phase 4
    Active, not recruiting

    Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

    Cannabidiol

    Lennox Gastaut Syndrome, Dravet Syndrome +1

    Enrollment
    154
    Start
    Jul 2021
    Primary Completion
    Aug 2027est.
    Completion
    Mar 2028est.
    NCT05044819
  • Phase 4
    Completed

    A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex

    Cannabidiol Oral Solution [Epidiolex]

    Tuberous Sclerosis Complex Associated Neuropsychiatric Disease

    Enrollment
    79
    Start
    Jun 2023
    Primary Completion
    Apr 2026
    Completion
    Apr 2026
    NCT05864846
  • Phase 4
    Completed

    A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy

    JZP258

    Narcolepsy

    Enrollment
    155
    Start
    Jun 2023
    Primary Completion
    Feb 2025
    Completion
    Mar 2025
    NCT05869773
  • Phase 4
    Completed

    A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy

    JZP258 (XYWAV)

    Idiopathic Hypersomnia, Narcolepsy

    Enrollment
    199
    Start
    Jul 2023
    Primary Completion
    Mar 2025
    Completion
    Mar 2025
    NCT05875974
  • Phase 4
    Not yet recruiting

    A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS

    Cannabidiol Oral Solution

    Lennox-Gastaut Syndrome

    Enrollment
    40
    Start
    Nov 2026est.
    Primary Completion
    Dec 2028est.
    Completion
    Dec 2028est.
    NCT07728097
  • Phase 3
    Completed

    Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy

    Xyrem, Xyrem Placebo

    Narcolepsy

    Enrollment
    231
    Start
    Apr 2003
    Primary Completion
    Jul 2004
    Completion
    Nov 2004
    NCT00066170
  • Phase 3
    Completed

    Experimental Medication For the Treatment of Generalized Anxiety Disorder

    experimental anti-anxiety drug

    Anxiety Disorder

    Enrollment
    511
    Start
    Nov 2004
    Primary Completion
    -
    Completion
    Dec 2005
    NCT00097708
  • Phase 3
    Completed

    A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder

    a benzodiazepine drug

    Anxiety Disorder

    Enrollment
    158
    Start
    Mar 2005
    Primary Completion
    -
    Completion
    Mar 2006
    NCT00106860
  • Phase 3
    Completed

    Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy

    Xyrem (sodium oxybate) oral solution

    Narcolepsy

    Enrollment
    59
    Start
    Oct 2004
    Primary Completion
    Sep 2007
    Completion
    Dec 2007
    NCT00132873
  • Phase 3
    Completed

    Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

    Defibrotide

    Severe Hepatic Veno-Occlusive Disease

    Enrollment
    134
    Start
    Jul 2006
    Primary Completion
    Sep 2008
    Completion
    Mar 2015
    NCT00358501
  • Phase 3
    Completed

    A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia

    Xyrem®, Placebo

    Fibromyalgia

    Enrollment
    548
    Start
    Aug 2006
    Primary Completion
    Sep 2008
    Completion
    Dec 2008
    NCT00371137
  • Phase 3
    Completed

    Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.

    Xyrem®

    Fibromyalgia

    Enrollment
    560
    Start
    Dec 2006
    Primary Completion
    Jan 2010
    Completion
    Jan 2010
    NCT00423605
  • Phase 3
    Completed

    A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.

    placebo, Xyrem®

    Fibromyalgia

    Enrollment
    573
    Start
    Dec 2006
    Primary Completion
    Apr 2009
    Completion
    Jun 2009
    NCT00423813
  • Phase 3
    Completed

    Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study

    Defibrotide, Defibrotide

    Hepatic Veno-Occlusive Disease

    Enrollment
    1,206
    Start
    Dec 2007
    Primary Completion
    Jul 2016
    Completion
    Sep 2016
    NCT00628498
  • Phase 3
    Completed

    A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy

    Placebo, Sativex®

    Palliative Care, Pain +1

    Enrollment
    177
    Start
    Feb 2002
    Primary Completion
    Feb 2004
    Completion
    Mar 2004
    NCT00674609
  • Phase 3
    Completed

    Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain

    Sativex, GW-2000-02

    Pain, Cancer

    Enrollment
    43
    Start
    Apr 2002
    Primary Completion
    Sep 2006
    Completion
    Sep 2006
    NCT00675948
  • Phase 3
    Completed

    A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis

    Sativex®, Placebo

    Detrusor Overactivity, Multiple Sclerosis

    Enrollment
    135
    Start
    Aug 2002
    Primary Completion
    Oct 2005
    Completion
    Oct 2005
    NCT00678795
  • Phase 3
    Completed

    A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)

    Sativex®, Placebo

    Spasticity, Multiple Sclerosis

    Enrollment
    572
    Start
    Jan 2008
    Primary Completion
    Jan 2009
    Completion
    Jan 2009
    NCT00681538
  • Phase 3
    Completed

    Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis

    Sativex, Placebo

    Spasticity, Multiple Sclerosis

    Enrollment
    36
    Start
    Nov 2007
    Primary Completion
    Jan 2009
    Completion
    Jan 2009
    NCT00702468
  • Phase 3
    Completed

    A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy

    Sativex, Placebo

    Pain, Diabetic Neuropathy

    Enrollment
    297
    Start
    Jul 2005
    Primary Completion
    Jun 2006
    Completion
    Jun 2006
    NCT00710424

1-25 of 206

…
Search ClinicalTrials.gov for “Jazz Pharmaceuticals”